The pharmaceutical industry‘s race for AI talent is prompting companies like Amgen to look beyond traditional healthcare backgrounds, reflecting a strategic shift that could transform drug discovery timelines. By recruiting expertise from consumer tech sectors, biotech firms aim to leverage artificial intelligence to address the inefficiencies of traditional drug development, which typically requires over a decade and billions in investment. This cross-industry talent acquisition represents a calculated bet that external AI perspectives can accelerate innovation in an industry ripe for technological disruption.
The unconventional hire: Amgen, the $151 billion biotech giant, recruited its head of artificial intelligence from Nike rather than from within the pharmaceutical industry.
- Dr. David Reese, Amgen’s first chief technology officer, deliberately sought talent outside traditional biotech, eventually bringing on Sean Bruich, who had spent 11 years at Nike after previous roles at Google and Facebook.
- Despite Bruich’s lack of molecular biology background, Reese specifically valued his external perspective, telling him during recruitment: “We’ve got those, they are really good, among the best in the world, and we need what you can bring to the table.”
Why this matters: The talent strategy reflects the pharmaceutical industry’s recognition that AI expertise is scarce within healthcare but essential for future competitiveness.
- Most elite data scientists have developed their expertise in consumer technology, finance, and other sectors rather than in healthcare environments.
- Amgen’s approach suggests that technical AI implementation skills may be more transferable across industries than previously assumed, particularly for scaling systems from proof-of-concept to enterprise-wide deployment.
The big picture: Amgen is betting on AI to dramatically improve the economics and timelines of drug development, currently one of the most expensive and time-consuming innovation processes in any industry.
- According to PhRMA, bringing a new drug from discovery to approval typically takes at least 10 years and costs an average of $2.6 billion.
- Dr. Reese, an oncologist by training who previously led Amgen’s R&D, believes recent AI advances represent “a once-in-a-generation moment that will ultimately change this industry” by potentially cutting years off development timelines.
Key initiatives: Amgen has already begun significant infrastructure investments to support its AI ambitions.
- The company installed an Nvidia supercomputer at its deCode genetics subsidiary in Reykjavik, Iceland, to analyze massive genetic datasets in search of new treatments.
- This computational power could be particularly valuable for tackling molecular-level complexities in conditions like lupus and other autoimmune diseases, according to Reese.
Bruich’s mandate: The new AI leader’s role encompasses both technical applications and organizational transformation.
- His responsibilities span from protein folding for drug design to streamlining regulatory filings, reflecting the breadth of AI’s potential impact across the pharmaceutical value chain.
- As Bruich explained: “My job is to figure out how to scale these things from proof points to systems that operate at enterprise levels.”
Recent Stories
DOE fusion roadmap targets 2030s commercial deployment as AI drives $9B investment
The Department of Energy has released a new roadmap targeting commercial-scale fusion power deployment by the mid-2030s, though the plan lacks specific funding commitments and relies on scientific breakthroughs that have eluded researchers for decades. The strategy emphasizes public-private partnerships and positions AI as both a research tool and motivation for developing fusion energy to meet data centers' growing electricity demands. The big picture: The DOE's roadmap aims to "deliver the public infrastructure that supports the fusion private sector scale up in the 2030s," but acknowledges it cannot commit to specific funding levels and remains subject to Congressional appropriations. Why...
Oct 17, 2025Tying it all together: Credo’s purple cables power the $4B AI data center boom
Credo, a Silicon Valley semiconductor company specializing in data center cables and chips, has seen its stock price more than double this year to $143.61, following a 245% surge in 2024. The company's signature purple cables, which cost between $300-$500 each, have become essential infrastructure for AI data centers, positioning Credo to capitalize on the trillion-dollar AI infrastructure expansion as hyperscalers like Amazon, Microsoft, and Elon Musk's xAI rapidly build out massive computing facilities. What you should know: Credo's active electrical cables (AECs) are becoming indispensable for connecting the massive GPU clusters required for AI training and inference. The company...
Oct 17, 2025Vatican launches Latin American AI network for human development
The Vatican hosted a two-day conference bringing together 50 global experts to explore how artificial intelligence can advance peace, social justice, and human development. The event launched the Latin American AI Network for Integral Human Development and established principles for ethical AI governance that prioritize human dignity over technological advancement. What you should know: The Pontifical Academy of Social Sciences, the Vatican's research body for social issues, organized the "Digital Rerum Novarum" conference on October 16-17, combining academic research with practical AI applications. Participants included leading experts from MIT, Microsoft, Columbia University, the UN, and major European institutions. The conference...